Hopital Saint Antoine
- Address
- lock Available on a paid plan
Hopital Saint Antoine - Advanced Oncology & Gastroenterology Research Center
Hopital Saint Antoine is a leading clinical research institution specializing in hematologic malignancies and gastrointestinal cancers. The center demonstrates particular expertise in multiple myeloma research, investigating novel therapeutic combinations including isatuximab, daratumumab, and CAR T-cell therapies for both newly diagnosed and relapsed/refractory disease. The facility conducts extensive trials in colorectal cancer, evaluating innovative approaches from neoadjuvant immunotherapy to circulating tumor DNA-guided treatment decisions.
- Multiple Myeloma and Lymphoma therapeutics, including bispecific antibodies and cellular therapies
- Colorectal and Gastrointestinal cancers, from early stage to metastatic disease
- Inflammatory Bowel Disease, including Crohn's disease and ulcerative colitis with microbiome-based interventions
- HIV research and novel antiretroviral strategies
The center's research portfolio extends to rare conditions including hereditary angioedema, gastrointestinal stromal tumors, and neuroendocrine carcinomas. Their inflammatory bowel disease program is particularly innovative, exploring fecal microbiota transplantation as maintenance therapy following immunosuppressive treatment withdrawal. Additionally, the center contributes to cardiovascular disease prevention trials, acute respiratory distress syndrome studies, and emergency medicine research, including novel approaches to hyperkalemia management and immunocompromised patient care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 22 therapeutic areas and 15 of 228 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 204 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital Saint Antoine
lock Showing 1 of 151 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients with Partial Lipodystrophy | Chiesi Farmaceutici S.p.A. | Phase III | Recruiting | Dec 2023 | — |
IMP list
lock Showing 1 of 228 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 24 | Unknown | 2014-12-23 | 2026-02-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.